ClinicalTrials.gg

TargetBeta

CDK2

cyclin dependent kinase 2 · Cyclin dependent kinases

10 programs in company-led studies act on CDK2, from 10 companies: 2 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
culmerciclibSino Biopharmaceuticalphase 3115 runningCDK4, CDK6the company's pipeline
CDK2 Inhibitor INCB123667ruleIncytephase 375 running–NCIt
vustanaciclibRegor Pharmaceuticalsphase 233 runningCDK4, CDK6a judged reading
tegtociclibPfizerphase 242 running–the company's pipeline
CDK2 Inhibitor AVZO-021ruleAvenzo Therapeuticsphase 222 running–NCIt
CDK2 Inhibitor ECI830Novartisphase 211 running–the company's pipeline
CDK2 Degrader BG-75098ruleBeOne Medicinesphase 111 running–NCIt
CG-7321ruleChengdu Cynogen Bio-pharmaceutical Tech.phase 111 runningCDK4the studies' text
nkt5097 cdk2ruleNiKang Therapeuticsphase 111 runningCDK4the studies' text
ZE94-0605ruleEilean Therapeuticsphase 111 running–the studies' text

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.